Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide
- Coagulation tests measure a person’s blood clotting ability, which can help doctors assess
risks of excessive bleeding or developing clots
- Agreement enables Abbott to provide coagulation testing solutions to labs with Sekisui’s new
- Sekisui is the #1 provider of high throughput coagulation systems in Japan
ABBOTT PARK, Ill. April 14, 2015/TOKYO, April 15, 2015 — Today, Abbott and Sekisui
announce an agreement to offer coagulation testing solutions for laboratories worldwide.
Coagulation tests measure a person’s blood clotting ability, which can help doctors assess risks
of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive
distributor of Sekisui’s new CP3000 coagulation instrument in the United States, Europe and
other regions that recognize CE Mark.
“Abbott is committed to providing testing solutions that healthcare providers rely on for
actionable information in diagnosing and treating various medical conditions,” said Jaime
Contreras, senior vice president, Commercial Operations, Diagnostics, Abbott. “Collaborating
with Sekisui broadens our offerings within hematology, providing an important component
needed to improve care for people around the world.”
Coagulation testing helps clinicians in assessing people before many medical treatments and in
monitoring those who take medications that can affect clotting. It is also useful in the diagnosis
of blood-related disorders, such as hemophilia (when blood does not clot normally) and
thrombosis (formation of a clot that blocks blood flow).
“Coagulation testing has been an important focus for Sekisui for over twenty years,” said Robert
Schruender, president and chief operating officer of Sekisui Diagnostics. “We are delighted that
this relationship with Abbott will bring the benefits of our system, which is a leading product in
Japan, to many customers around the world.”
Sales of the CP3000 are expected to begin later this year in Europe, countries that recognize CE
Mark and non-regulated countries, and in the United States in 2016. Abbott will have nonexclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.
About the CP3000:
The Sekisui CP3000 system features high-quality reagents, small sample volume requirements
and offers a combination of high-throughput and a compact footprint. With a broad assay menu
and rapid result turnaround time, the CP3000 can rapidly meet the workflow needs of
laboratories of all sizes, while providing high quality and reliable results. The system will aim to
seamlessly connect to Abbott’s ACCELERATOR a3600 lab automation platform and middleware
Sekisui Medical (SMD) headquartered in Tokyo, Japan, aspires to become a leading global
medical company in fields such as Diagnostics, Pharmaceuticals & Fine Chemicals, and ADME &
Toxicology Research. The Diagnostics business is engaged in the development, manufacture and
distribution of commercial plastic vacuum blood collection tubes, and various in vitro diagnostics
products and systems, including coagulation.
Sekisui Diagnostics, a global diagnostics company and sister company of SMD, is committed to
improving patient’s lives by providing innovative medical diagnostics to physicians and
laboratories through a global commercial network. Product lines include clinical chemistry and
coagulation systems, reagents, infectious disease testing and rapid test kits, as well as enzymes
and specialty bio-chemicals.
Abbott is a global healthcare company devoted to improving life through the development of
products and technologies that span the breadth of healthcare. With a portfolio of leading,
science-based offerings in diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
Darcy Ross, +1 (224) 667-3655
Rachael Jarnagin, +1 (224) 668-6552
Tina Ventura, +1 (224) 668-7606
Lisa Williams, +1 (858) 777-2660